FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1
Clinical trials for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for FSHD: experimental drug AOC 1020 completes early testing
Disease control CompletedThis study tested a new medicine called AOC 1020 in 90 adults with FSHD, a genetic muscle-weakening disease. The goal was to check if the drug is safe and to measure how it moves through the body. Participants received either the drug or a placebo by IV, and researchers looked fo…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1
Phase: PHASE1, PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Sound waves reveal hidden facial muscle damage in rare disease
Knowledge-focused CompletedThis study tested whether ultrasound can detect early facial muscle changes in people with facioscapulohumeral muscular dystrophy (FSHD), a rare muscle disease. Researchers compared 20 FSHD patients with 19 healthy adults, measuring muscle thickness and echo intensity in key faci…
Matched conditions: FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1
Sponsor: Koç University • Aim: Knowledge-focused
Last updated May 14, 2026 12:06 UTC